The drugmaker will cut 340 jobs, which is expected to save $170 million annually. A majority of the job cuts will affect the commercial operations of its postpartum depression drug Zulresso.
In December, Sage faced a significant setback after a disappointing Phase 3 clinical trial for its depression drug called zuranolone, or SAGE-217, according to Stat. The results cut more than $6 billion from its market value.
Sage expects to incur a one-time charge of $31 million due to the reduction of workforce, but expects to be able to sustain operations through 2022 with the cuts.
“The headwinds we are facing individually and collectively, along with a recognition of our need to move forward as a company, have led to this difficult decision. We believe this cost reduction and reallocation of resources will help Sage advance our portfolio in a way that is consistent with our mission of delivering medicines that matter to people with serious brain health disorders,” said Jeff Jonas, MD, CEO of Sage Therapeutics.
More articles on pharmacy:
Gilead boosts remdesivir production, now has 1.5M doses
Walgreens adds 6 COVID-19 safety measures to protect workers
2 East Coast pharmacy schools graduating students early to fight COVID-19
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
